These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19056949)

  • 21. Screening of dystrophin gene deletions in Malaysian patients with Duchenne muscular dystrophy.
    Marini M; Salmi AA; Watihayati MS; SMardziah MD; Zahri MK; Hoh BP; Ankathil R; Lai PS; Zilfalil BA
    Med J Malaysia; 2008 Mar; 63(1):31-4. PubMed ID: 18935728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
    Lai Y; Li D; Yue Y; Duan D
    Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deletion of exon 16 of the dystrophin gene is not associated with disease.
    Schwartz M; Dunø M; Palle AL; Krag T; Vissing J
    Hum Mutat; 2007 Feb; 28(2):205. PubMed ID: 17226814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy].
    Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmunity in a genetic disease—a cautionary tale.
    Moore MJ; Flotte TR
    N Engl J Med; 2010 Oct; 363(15):1473-5. PubMed ID: 20925551
    [No Abstract]   [Full Text] [Related]  

  • 26. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
    Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
    Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2.
    Flanigan KM; Wein N; Gurvich OL; Howard MT; Weiss RB
    Neuromuscul Disord; 2013 Feb; 23(2):192. PubMed ID: 23369578
    [No Abstract]   [Full Text] [Related]  

  • 28. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naked plasmid DNA for the treatment of muscular dystrophy.
    Braun S
    Curr Opin Mol Ther; 2004 Oct; 6(5):499-505. PubMed ID: 15537051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetics. A genetic intervention stands a skip away from clinical tests.
    Chamberlain JS
    Science; 2012 Dec; 338(6113):1431-2. PubMed ID: 23239725
    [No Abstract]   [Full Text] [Related]  

  • 31. Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?
    Lim LE; Rando TA
    Nat Clin Pract Neurol; 2008 Mar; 4(3):149-58. PubMed ID: 18268530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
    Banks GB; Chamberlain JS
    Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of Duchenne muscular dystrophy by induction of skipping of dystrophi exon].
    Matsuo M; Yagi M; Takeshima Y
    Rinsho Shinkeigaku; 2006 Nov; 46(11):936-8. PubMed ID: 17432225
    [No Abstract]   [Full Text] [Related]  

  • 34. Duchenne muscular dystrophy in monozygotic twins.
    Kulkarni ML; Keshavamurthy KS
    Indian Pediatr; 2004 Mar; 41(3):290-1. PubMed ID: 15064524
    [No Abstract]   [Full Text] [Related]  

  • 35. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion.
    Ferreiro V; Giliberto F; Muñiz GM; Francipane L; Marzese DM; Mampel A; Roqué M; Frechtel GD; Szijan I
    Muscle Nerve; 2009 Feb; 39(2):239-43. PubMed ID: 19012301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.
    Moulton HM; Wu B; Jearawiriyapaisarn N; Sazani P; Lu QL; Kole R
    Ann N Y Acad Sci; 2009 Sep; 1175():55-60. PubMed ID: 19796077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental therapy in Duchenne muscular dystrophy].
    van den Bergen JC; Straathof CS; Aartsma-Rus A; Ginjaar IB; Verschuuren JJ
    Ned Tijdschr Geneeskd; 2009 May; 153(18):870-5. PubMed ID: 19475867
    [No Abstract]   [Full Text] [Related]  

  • 38. [Exon skipping therapy for Duchenne muscular dystrophy: outcome of preclinical study and prospective for clinical study].
    Nakamura A; Takeda S
    No To Hattatsu; 2010 Mar; 42(2):117-23. PubMed ID: 23858595
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When running a stop sign may be a good thing.
    Karpati G; Lochmuller H
    Ann Neurol; 2001 Jun; 49(6):693-4. PubMed ID: 11409418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.